Skip to main content
. Author manuscript; available in PMC: 2012 Feb 15.
Published in final edited form as: Environ Mol Mutagen. 2011 Mar;52(2):153–160. doi: 10.1002/em.20595

Figure 3. Cell survival results for DT40 cells and their isogenic mutants continuously exposed to cisplatin.

Figure 3

(A) Survival percentage for each cell line exposed to cisplatin compared with concurrent control. (B) Survival data were log-transformed giving approximate normality. Black columns indicate significant differences analyzed by ANCOVA (p<0.01) between parental DT40 cells and mutants (BLM and XRCC2 cells). In contrast, FEN1-deficient cells showed no significant difference by ANCOVA (p>0.05). Bars: 95% confidence intervals for LC50 value for each cell line.